Profiling prostate cancer

	Tweet

A large scale genetic analysis of multiple prostate cancer samples, published online by Cell Press on June 24th in the journal Cancer Cell, is providing exciting new insight into the disease and may lead to more effective treatment strategies. In addition, the freely available genetic and clinical outcome data obtained in the study represents a valuable public resource for the cancer research community.

Prostate cancer is clinically diverse with some patients developing fatal metastatic disease within a couple of years and others living for decades. This suggests that prostate tumors may have a substantial underlying genetic diversity. Although large-scale genomic characterization projects have provided helpful insight into the molecular classification of many other types of cancer, similar studies of prostate cancer have proven to be more of a challenge.

“Our current knowledge of prostate cancer genomes is largely based on small groups of patients,” says senior study author, Dr. Charles Sawyers from Memorial Sloan-Kettering Cancer Center.

"To obtain a more comprehensive picture of prostate cancer genomics, we adopted an integrated comprehensive approach to analyze 218 primary and metastatic prostate cancer as well as 12 cell lines.”

Dr. Sawyers and colleagues found that an integrative analysis revealed a much higher frequency of alterations in the androgen receptor pathway than previously suspected, including amplification or mutation of the NCOA2 gene, an amplifier of androgen receptor output. Importantly, the pattern of DNA copy number alterations defined subsets of low- and high-risk disease in primary samples, raising the possibility of a test that could predict who needs aggressive therapy versus watchful waiting.

“Taken together, our findings clarify the role of several known cancer pathways in prostate cancer, implicate several new ones, and provide a blueprint for clinical development of pathway inhibitors,” says Dr. Sawyers.

All the data obtained in the study was made available through an easily accessible web-based application. “The high prevalence of prostate cancer, which is the most common malignancy in males, and the relative paucity of large comprehensive genomic datasets in the disease make this a unique public resource for the cancer research community,” concludes Dr. Sawyers.

###

Contact: Cathleen Genova

617-397-2802
Cell Press

RELATED STORIES:
Moderate exercise may lower prostate cancer risk   Two New Risk Indicators For Prostate Cancer Revealed   U.S. Trial Shows No Early Mortality Benefit from Annual Prostate Cancer Screening   Obesity linked with higher prostate cancer risk   Higher doses of radiation for prostate cancer do not decrease sexual function   deCODE discovers genetic markers that improve the power of PSA testing for detecting prostate cancer   Prostate cancer patients see high survival rates with seed implants   Radiation added to hormone therapy increases survival for men with prostate cancer   Sweeping View of Prostate Cancer Genome Yields Deep Insights   Prostate Cancer Etiology   Sometimes No Treatment is the Right Option for Low-Risk Prostate Cancer   Many prostate cancers don’t need radical therapy   Shorter radiation course as effective as standard therapy for prostate cancer recurrence   Scientists discover way to block growth of prostate cancer cells   New X-ray approach targets prostate cancer   Delaying therapy OK for low-risk prostate cancer   Red Wine Compound Shown To Prevent Prostate Cancer   Prostate test ‘public health disaster’ - discoverer   Childless men run lower risk of prostate cancer   PSA Predicts Treatment Success in Advanced Prostate Cancer   First Biomarker Discovered that Predicts Prostate Cancer Outcome   Smoking Associated with Worse Outcomes in Patients with Prostate Cancer Treated by Radical Radiother

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]